⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from Neoantigen targetability in progressive advanced melanoma

Jitske van den Bulk Els M.E. Verdegaal Manon van der Ploeg Marten Visser Joana B. Nunes Arnoud H. de Ru Rayman T.N. Tjokrodirijo Marieke E. Ijsselsteijn Natasja I. Janssen Ruud van der Breggen Linda de Bruin Pita de Kok George M.C. Janssen Dina Ruano Ellen Kapiteijn Peter A. van Veelen Noel F.C.C. de Miranda Sjoerd H. van der Burg

View at Publisher

Ask AI

Bookmark

Share

Abstract

HLA class I and II expression on melanoma cell lines derived from early and later metastatic lesions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bulk et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522697 https://doi.org/10.1158/1078-0432.27034126

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Neoantigen targetability in progressive advanced melanoma2024
2Supplementary Figure S3 from Neoantigen targetability in progressive advanced melanoma2024
3Supplementary Figure S3 from Neoantigen targetability in progressive advanced melanoma2024
4Supplementary Figure S4 from Neoantigen targetability in progressive advanced melanoma2024
5Supplementary Figure S4 from Neoantigen targetability in progressive advanced melanoma2024

Supplementary Figure S6 from Neoantigen targetability in progressive advanced melanoma2024
Supplementary Figure S6 from Neoantigen targetability in progressive advanced melanoma2024
Supplementary Figure S5 from Neoantigen targetability in progressive advanced melanoma2024